Early Phase CRA II | Lead, UK Trials & Site Partnerships

KCR Placement; Reading; Vor Ort; GBP 42.000 - 64.000; Vollzeit

Benefits dieser Stelle

Annual leave

Health insurance

Pension plan

Employee assistance programme

Zusammenfassung

ICON plc is seeking an experienced CRA II or Senior CRA to join our Early Phase team in the UK. You will monitor a small portfolio of 3–4 sites across the country, maintaining high quality oversight, patient safety and data integrity in early development studies.

Working with investigators and sponsors, you’ll manage qualification, initiation, monitoring and close-out activities while mentoring less experienced colleagues and ensuring regulatory compliance across trials.

Qualifikationen

• ICH-GCP knowledge and regulatory understanding.
• Strong relationship-building and communication skills.
• Ability to travel across the UK and work independently in a global study team.

Aufgaben

• Manage site qualification, initiation, monitoring and close-out across UK Early Phase studies.
• Build partnerships with investigators and site teams to ensure study success.
• Ensure patient safety, protocol compliance and data integrity throughout the trial lifecycle.
• Review study data, resolve site queries and mitigate risks proactively.
• Support sponsors and project teams with early development programme challenges.
• Provide guidance to sites and internal stakeholders as a clinical research expert.

Kenntnisse

Independent monitoring

Communication skills

Travel readiness

Ausbildung

Life Science degree

Nursing degree

Pharmacy degree

Jobbeschreibung

ICON plc is seeking an experienced CRA II or Senior CRA to join our Early Phase team in the UK. You will monitor a small portfolio of 3–4 sites across the country, maintaining high quality oversight, patient safety and data integrity in early development studies.

Working with investigators and sponsors, you’ll manage qualification, initiation, monitoring and close-out activities while mentoring less experienced colleagues and ensuring regulatory compliance across trials.